Lymphatic System Disease disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: LYM024 MIFTS: 49	Lymphatic System Disease Categories: Cardiovascular diseases, Fetal diseases, Immune diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Lymphatic System Disease

MalaCards integrated aliases for Lymphatic System Disease:

Name: Lymphatic System Disease ¹¹ ¹⁴ ¹⁶

Lymphatic Diseases ⁴¹ ⁴³ ⁷¹

Lymphatic Disease ¹¹ ⁷⁵

Disorder of Lymph Node and Lymphatics ¹¹

Abnormality of the Lymphatic System ²⁸

Disorder of Lymphatic System ¹¹

Disorder of Lymphoid System ¹¹

Disease of Lympoid System ¹¹

Lympoid System Disease ¹¹

Lymphatic Disorder ¹¹

Lymphangiopathy ¹¹

Adenopathy ¹⁴

Classifications:

MalaCards categories:
Global: Fetal diseases Rare diseases
Anatomical: Immune diseases Cardiovascular diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹¹ DOID:75

MeSH ⁴³ D008206

SNOMED-CT ⁶⁸ 266326002

EFO ¹⁶ EFO_0007352

UMLS ⁷¹ C0024228

Sources

Summaries for Lymphatic System Disease

MedlinePlus: ⁴¹ The lymphatic system is a network of tissues and organs. It is made up of: Lymph - a fluid that contains white blood cells that defend against germs Lymph vessels - vessels that carry lymph throughout your body. They are different from blood vessels. Lymph nodes - glands found throughout the lymph vessels. Along with your spleen, these nodes are where white blood cells fight infection. Your bone marrow and thymus produce the cells in lymph. They are part of the system, too. The lymphatic system clears away infection and keeps your body fluids in balance. If it's not working properly, fluid builds in your tissues and causes swelling, called lymphedema. Other lymphatic system problems can include infections, blockage, and cancer.

MalaCards based summary: Lymphatic System Disease, also known as lymphatic diseases, is related to histiocytosis and squamous cell carcinoma, head and neck, and has symptoms including edema, axillary lymph node pain and axillary lymph node tenderness. An important gene associated with Lymphatic System Disease is MIR199A1 (MicroRNA 199a-1), and among its related pathways/superpathways are miRNAs involved in DNA damage response and Cell differentiation - expanded index. The drugs D-Tyrosine and Immunoglobulins have been mentioned in the context of this disorder. Affiliated tissues include lymphatic system, lymph node and bone marrow.

Disease Ontology: ¹¹ An immune system disease that is located in the lymphatic system.

Wikipedia: ⁷⁵ Lymphatic disease is a class of disorders which directly affect the components of the lymphatic... more...

Sources

Related Diseases for Lymphatic System Disease

Diseases in the Lymphatic System Disease family:

Rare Lymphatic System Anomaly

Diseases related to Lymphatic System Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 682)

#	Related Disease	Score	Top Affiliating Genes
1	histiocytosis	32.5	U2AF1 SERPINA3 CCR6
2	squamous cell carcinoma, head and neck	31.2	U2AF1 MIR9-1 MIR21 MIR200B MIR199A1 MIR18A
3	renal cell carcinoma, nonpapillary	31.1	U2AF1 MIR9-1 MIR34A MIR21 MIR199A1 MIR18A
4	prostate cancer	31.1	SERPINA3 MIR34A MIR21 MIR200B MIR199A1 MIR181A1
5	immune deficiency disease	31.0	SERPINA3 MIR9-1 MIR34A MIR21 MIR199A1 MIR181A1
6	lymphangioma	31.0	SERPINA3 MIR199A1 MIR18A MIR15A H2AC18 CCR6
7	lung cancer	31.0	U2AF1 SERPINA3 MIR9-1 MIR34A MIR21 MIR200B
8	respiratory failure	30.9	SERPINA3 MIR21 MIR199A1 MIR17 MIR155 MIR142
9	esophageal cancer	30.8	MIR9-1 MIR34A MIR21 MIR200B MIR199A1 MIR18A
10	aortic valve disease 2	30.8	SERPINA3 MIR34A MIR21 MIR199A1 MIR17 MIR150
11	polyclonal hypergammaglobulinemia	30.8	SERPINA3 ICOSLG CCR6
12	exanthem	30.8	ICOSLG H2AC18 CCR6
13	myeloma, multiple	30.7	U2AF1 MIR9-1 MIR21 MIR199A1 MIR181A1 MIR17
14	angioimmunoblastic t-cell lymphoma	30.7	MIR155 KDM4C IRF4 ICOSLG CCR6
15	leukemia, acute lymphoblastic	30.7	U2AF1 MIR9-1 MIR21 MIR199A1 MIR18A MIR181A1
16	systemic scleroderma	30.7	MIR21 MIR142 ICOSLG H2AC18 CCR6
17	suppression of tumorigenicity 12	30.7	U2AF1 SERPINA3 KDM4C ICOSLG H2AC18
18	pancreatic cancer	30.7	SERPINA3 MIR34A MIR21 MIR199A1 MIR181A1 MIR17
19	lymphoma, non-hodgkin, familial	30.7	U2AF1 SERPINA3 MIR9-1 MIR34A MIR21 MIR200B
20	nasopharyngeal carcinoma	30.7	MIR9-1 MIR21 MIR18A MIR17 MIR155 MIR150
21	larynx cancer	30.6	MIR21 MIR17 MIR155 MIR142
22	polymyositis	30.6	MIR34A MIR21 MIR155
23	cervix carcinoma	30.5	U2AF1 SERPINA3 MIR9-1 MIR21 MIR199A1 MIR15A
24	leukemia, chronic myeloid	30.5	U2AF1 MIR9-1 MIR199A1 MIR18A MIR17 MIR155
25	mantle cell lymphoma	30.5	U2AF1 MIR9-1 MIR17 MIR155 KDM4C IRF4
26	peripheral t-cell lymphoma	30.5	MIR21 MIR199A1 MIR17 MIR155 KDM4C ICOSLG
27	hypertrophic cardiomyopathy	30.5	SERPINA3 MIR21 MIR199A1 MIR17 MIR142 MIR126
28	aortic disease	30.5	SERPINA3 MIR34A MIR21 MIR199A1 MIR181A1 MIR17
29	t-cell acute lymphoblastic leukemia	30.5	U2AF1 MIR9-1 MIR17 MIR155 MIR142 KDM4C
30	intestinal disease	30.5	U2AF1 SERPINA3 MIR9-1 MIR34A MIR21 MIR200B
31	viral infectious disease	30.5	SERPINA3 MIR21 MIR199A1 MIR155 ICOSLG H2AC18
32	sarcoidosis 1	30.5	SERPINA3 MIR155 MIR150 ICOSLG CCR6
33	myelodysplastic syndrome	30.5	U2AF1 MIR9-1 MIR34A MIR199A1 MIR17 MIR150
34	peripheral nervous system disease	30.5	U2AF1 SERPINA3 MIR9-1 MIR34A MIR21 MIR200B
35	skin carcinoma	30.5	MIR21 MIR199A1 MIR18A KDM4C ICOSLG H2AC18
36	allergic disease	30.5	SERPINA3 MIR21 MIR155 ICOSLG H2AC18 CCR6
37	leukemia, chronic lymphocytic	30.5	U2AF1 MIR9-1 MIR34A MIR21 MIR200B MIR199A1
38	lung disease	30.5	SERPINA3 MIR21 MIR199A1 MIR17 MIR142 MIR126
39	plasma cell neoplasm	30.5	U2AF1 MIR181A1 MIR17 MIR155 MIR142 MIR126
40	breast cancer	30.5	SERPINA3 MIR9-1 MIR34A MIR21 MIR200B MIR199A1
41	chromosomal disease	30.5	U2AF1 SERPINA3 MIR9-1 MIR21 MIR200B MIR199A1
42	interstitial lung disease	30.5	SERPINA3 MIR21 MIR200B MIR199A1 MIR155 MIR142
43	lymphoma, hodgkin, classic	30.5	MIR9-1 MIR21 MIR18A MIR155 KDM4C IRF4
44	lymph node disease	30.5	SERPINA3 MIR150 ICOSLG H2AC18 CCR6
45	gallbladder disease	30.5	SERPINA3 MIR199A1 MIR17 MIR142 CCR6
46	crohn's disease	30.5	SERPINA3 MIR21 MIR142 ICOSLG H2AC18 CCR6
47	mycobacterium tuberculosis 1	30.5	SERPINA3 MIR21 MIR155 ICOSLG H2AC18 CCR6
48	autoimmune lymphoproliferative syndrome	30.5	U2AF1 MIR21 ICOSLG CCR6
49	laryngeal disease	30.5	MIR21 MIR17 MIR155 MIR142 CCR6
50	head and neck cancer	30.5	U2AF1 MIR9-1 MIR34A MIR21 MIR200B MIR199A1

Graphical network of the top 20 diseases related to Lymphatic System Disease:

Sources

Symptoms & Phenotypes for Lymphatic System Disease

UMLS symptoms related to Lymphatic System Disease:

edema; axillary lymph node pain; axillary lymph node tenderness

Sources

Drugs & Therapeutics for Lymphatic System Disease

Drugs for Lymphatic System Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 56)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

D-Tyrosine

Approved, Experimental, Investigational, Nutraceutical

Phase 3

133585-56-5, 60-18-4, 556-02-5

1153 6057

Immunoglobulins

Phase 3

Antibodies

Phase 3

Cisplatin

Approved

Phase 2

15663-27-1

2767 5702198 441203

Rituximab

Approved

Phase 2

174722-31-7

Dexamethasone acetate

Approved, Investigational, Vet_approved

Phase 2

1177-87-3

3680

Dexamethasone

Approved, Investigational, Vet_approved

Phase 2

50-02-2

3003 5743

Gemcitabine

Approved

Phase 2

95058-81-4, 122111-03-9

60750

Sodium citrate

Approved, Investigational

Phase 2

68-04-2

23431961

Sildenafil

Approved, Investigational

Phase 2

139755-83-2, 171599-83-0

5212 135398744

Cyclophosphamide

Approved, Investigational

Phase 2

50-18-0, 6055-19-2

2907

Etoposide

Approved

Phase 2

33419-42-0

36462

Prednisone

Approved, Vet_approved

Phase 2

53-03-2

5865

Doxorubicin

Approved, Investigational

Phase 2

23214-92-8

31703

Brentuximab vedotin

Approved, Investigational

Phase 2

914088-09-8

Citric acid

Approved, Nutraceutical, Vet_approved

Phase 2

77-92-9

311

Phosphodiesterase Inhibitors

Phase 2

Phosphodiesterase 5 Inhibitors

Phase 2

Vasodilator Agents

Phase 2

Citrate

Phase 2

Etoposide phosphate

Phase 2

16760419

Liposomal doxorubicin

Phase 2

Bromides

Phase 2

Anticonvulsants

Phase 2

Bendamustine Hydrochloride

Phase 2

Alkylating Agents

Phase 2

Antineoplastic Agents, Alkylating

Phase 2

Antineoplastic Agents, Immunological

Phase 2

Levoleucovorin

Approved, Experimental, Investigational

Phase 1

68538-85-2, 58-05-9, 73951-54-9

149436 6006

Pyrimethamine

Approved, Investigational, Vet_approved

Phase 1

58-14-0, 19085-09-7

4993

Fludarabine

Approved

Phase 1

75607-67-9, 21679-14-1

30751 657237

Folic acid

Approved, Nutraceutical, Vet_approved

Phase 1

59-30-3

6037

Anti-Infective Agents

Phase 1

Folic Acid Antagonists

Phase 1

Folate

Phase 1

Vitamin B9

Phase 1

Antiprotozoal Agents

Phase 1

Antiparasitic Agents

Phase 1

Vitamin B Complex

Phase 1

Antimalarials

Phase 1

Antirheumatic Agents

Phase 1

Immunosuppressive Agents

Phase 1

Immunologic Factors

Phase 1

Inosine pranobex

Approved

36703-88-5

Zidovudine

Approved

30516-87-1

35370

Acetaminophen

Approved

103-90-2

1983

Diphenhydramine

Approved, Investigational

147-24-0, 58-73-1

3100

Promethazine

Approved, Investigational

60-87-7

4927

Anesthetics

Antiviral Agents

Interventional clinical trials:

(show all 35)

#	Name	Status	NCT ID	Phase	Drugs
1	Effectiveness of Intracavitary Manual Lymphatic Drainage Versus Conventional Treatment in the Prevention of Perineal Trauma During Labor.	Completed	NCT02960841	Phase 4
2	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Zilovertamab (an ROR1 Antibody) Plus Ibrutinib Versus Ibrutinib Plus Placebo in Subjects With Relapsed or Refractory Mantle Cell Lymphoma	Not yet recruiting	NCT05431179	Phase 3	Zilovertamab;Ibrutinib;Placebo
3	A Non-randomized, Open-label, Phase II Study of Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) Not Suitable for Transplantation	Unknown status	NCT03373019	Phase 2	Chidamide combined with R-GDP
4	Micro-mobile Foot Compression Device to Improve Motor-function in People With Diabetes and Loss of Protective Sensation	Completed	NCT03135535	Phase 2
5	Phase 2 Study of Sildenafil for the Treatment of Lymphatic Malformations	Completed	NCT02335242	Phase 2	Sildenafil 20 mg tablets
6	Phase II Study on the Role of Brentuximab Vedotin as Single Agent in the Treatment of Relapsed/Refractory CD30 Positive Peripheral T Cell Lymphoma (PTCL) Patients	Completed	NCT02497131	Phase 2	Brentuximab Vedotin
7	Phase Ib/II Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Relapsed/Refractory CD30+ Hodgkin's Lymphoma and CD30+ Non-Hodgkin's Lymphoma	Recruiting	NCT02690545	Phase 1, Phase 2
8	Interest of Bilateral Basic Tongue Mucosectomy Assisted by Robot or Laser in Combination With Tonsillectomy in the Assessment of Prevalent Cervical Lymphadenopathy: a Randomized Phase II Study	Recruiting	NCT04767048	Phase 2
9	A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting	Active, not recruiting	NCT03744676	Phase 2
10	Brentuximab Vedotin With Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (BV-CHEP) for the Treatment of Adult T-Cell Leukemia/Lymphoma: A Pilot Study of the Rare Lymphoma Working Group	Active, not recruiting	NCT03264131	Phase 2	Brentuximab Vedotin;CHEP
11	A Phase 2, Multicenter, Open Label Dose-ranging Study of Sepantronium Bromide in Patients With Relapsed/Refractory c-Myc Rearranged High-grade B-cell Lymphoma (HGBCL)	Not yet recruiting	NCT05263583	Phase 2	Sepantronium Bromide
12	A Phase II Study With Bendamustine Plus Brentuximab Vedotin in Hodgkin's Lymphoma and CD30+ Peripheral T-cell Lymphoma in First Salvage Setting: the BBV Regimen.	Terminated	NCT02499627	Phase 2	Brentuximab Vedotin;Bendamustine
13	Pilot (Phase I-II) Study of Pyrimethamine (Daraprim) for the Treatment of the Autoimmune Lymphoproliferative Syndrome (ALPS)	Completed	NCT00065390	Phase 1	Pyrimethamine
14	A Phase I Study of Autologous Activated T-cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch in Subjects With Relapsed/Refractory B-cell Lymphoma	Recruiting	NCT03696784	Phase 1	Bendamustine;Fludarabine;AP1903;Cyclophosphamide
15	Phase I Study of the Administration of T Lymphocytes Co-Expressing the CD30 Chimeric Antigen Receptor (CAR) and CCR4 for Relapsed/Refractory CD30+ Hodgkin Lymphoma and Cutaneous T-Cell Lymphoma	Recruiting	NCT03602157	Phase 1	Bendamustine;Fludarabine
16	Application of 68Ga NEB PET Imaging in the Diagnosis and Evaluation of Lymphatic Disorders, Including Lymphedema, Lymphangioma, Lymphangioleiomyomatosis, Plastic Bronchitis, Lymphadenopathy Caused by Rheumatoid Arthritis, Etc.	Recruiting	NCT04273334	Phase 1	68Ga-NEB
17	Phase I Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Prevention of Relapse of CD30+ Lymphomas After High Dose Therapy and Autologous Stem Transplantation (ATLAS)	Active, not recruiting	NCT02663297	Phase 1	ATLCAR.CD30 cells
18	Phase I/II Combinational Investigational New Drug Application: Imaging Lymphatic Function in Normal Subjects and in Persons With Lymphatic Disorders	Unknown status	NCT00833599		NIRFLI with ICG
19	Endobronchial Ultrasound Transbronchial Needle Aspiration (EBUS-TBNA) Versus Flexible 19G Endobronchial Ultrasound Transbronchial Needle (Flex 19G EBUS-TBNA) in the Assessment of Mediastinal and Hilar Lymph-adenopathy: a Randomised Trial	Unknown status	NCT02916459
20	Analyse du caractère prédictif de l'échographie Ganglionnaire Pour le Diagnostic de bégninité ou malignité d'Une adénopathie Superficielle	Unknown status	NCT02645825
21	Prospective Trial Comparing the Diagnostic Yield of Two Different Needle Sizes Used in EBUS-TBNA for Sarcoidosis and Lymphoma	Unknown status	NCT03573362
22	"Effects of Different Manoeuvres of Manual Lymphatic Drainage in the Neck on Systems Nervous, Cardiovascular, Respiratory and Lymphatic in Healthy Subjects. Experimental Randomized Crossover Study"	Completed	NCT03709407
23	Dynamic Contrast Enhanced MR Lymphangiogram Imaging of Lymphatic Anomalies (LA)	Completed	NCT02744027
24	A Multi-Center Double-Blind Placebo-Controlled Study to Investigate the Action of Isoprinosine (Inosiplex) in Patients With Unexplained Generalized Lymphadenopathy	Completed	NCT00002297		Inosine pranobex
25	A Multi-Center Randomized Double-Blind Placebo-Controlled Study To Investigate the Effect of Isoprinosine in Immunodepressed Patients With Uncomplicated Generalized Lymphadenopathy	Completed	NCT00002061		Inosine pranobex
26	A Multi-Center Randomized Double-Blind Placebo-Controlled Study to Investigate the Effect of Isoprinosine in Immunodepressed Patients With Uncomplicated Generalized Lymphadenopathy	Completed	NCT00002296		Inosine pranobex
27	Investigation of the Effect of Manual Lymphatic Drainag on Venous Ulcer Healing Rate	Completed	NCT04461132
28	The Efficacy and Safety of Retrovir in Patients Infected With HIV Who Are Asymptomatic (CDC Group II) or Have Persistent Generalized Lymphadenopathy (CDC Group III)	Completed	NCT00002048		Zidovudine
29	Transbronchial Needle Aspiration With and Without Rapid On-site Cytopathologic Evaluation in the Diagnostic Approach to Hilar/Mediastinal Adenopathy: A Randomized Controlled Trial.	Completed	NCT00915330
30	Prospective Study to Evaluate Mapleson Circuit With Monitored Anesthesia Care During EBUS Bronchoscopy	Completed	NCT03815097
31	An Observational Long-term Safety and Efficacy Follow-up Study After Ex-vivo Gene Therapy With BIVV003 in Participants With Severe Sickle Cell Disease (SCD) or With ST-400 in Participants With Transfusion-dependent Beta-thalassemia (TDT) With Autologous Hematopoietic Stem Cell Transplant	Recruiting	NCT05145062		BIVV003;ST-400
32	Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units	Recruiting	NCT01451502
33	Lymphaticovenous Anastomosis as a Surgical Treatment for Breast Cancer-Related Lymphedema	Recruiting	NCT05441943
34	Characterization of the Pathogenesis of Primary and Secondary Lymphatic Disorders	Recruiting	NCT02156115
35	The International Lymphatic Disease and Lymphedema Patient Registry and Biorepository	Recruiting	NCT01336790

Search NIH Clinical Center for Lymphatic System Disease

Cochrane evidence based reviews: lymphatic diseases

Sources

Genetic Tests for Lymphatic System Disease

Genetic tests related to Lymphatic System Disease:

#	Genetic test	Affiliating Genes
1	Abnormality of the Lymphatic System ²⁸

Sources

Anatomical Context for Lymphatic System Disease

Organs/tissues related to Lymphatic System Disease:

FMA: Lymphatic System

MalaCards : Lymph Node, Bone Marrow, Thymus, Spleen, Bone, Breast, T Cells

Sources

Publications for Lymphatic System Disease

Articles related to Lymphatic System Disease:

(show top 50) (show all 4552)

#	Title	Authors	PMID	Year
1	Exploring disease interrelationships in patients with lymphatic disorders: A single center retrospective experience. ⁶² ⁴¹	Rockson SG...Nicolls MR	35452183	2022
2	Intrathyroidal ectopic thymus: an important entity in the differential diagnosis of thyroid nodules. ⁴¹	Cimbek EA...Karaguzel G	36305441	2022
3	A Proposed Link Between Acute Thymic Involution and Late Adverse Effects of Chemotherapy. ⁴¹	Lagou MK...Karagiannis GS	35844592	2022
4	Axillary adenopathy detected on breast MRI following COVID-19 vaccination: outcomes and follow-up recommendations. ⁶²	Nguyen DL...Ambinder EB	36335676	2023
5	Radiographic features of pneumonitis in patients treated with immunotherapy compared to traditional chemotherapy for non-small cell lung cancer. ⁶²	Capaccione KM...Salvatore MM	35307225	2023
6	[Limitations of the Xpert-MTB/RIF® assay in the initial diagnosis of tuberculosis in the context of a rural hospital in Ethiopia]. ⁶²	Comeche B...Ramos-Rincon JM	36129757	2022
7	Malignant solitary fibrous tumor of the floor of the mouth in a 71-year-old male: A case report. ⁶²	Miller R...Shifteh K	36238206	2022
8	Prophylactic Lymphaticovenous Anastomosis Performed with Lymphadenectomy is Oncologically Safe for Melanoma. ⁶²	Xia TY...Gastman BR	36471187	2022
9	Compression therapy, autonomic nervous system, and heart rate variability: A narrative review and our preliminary personal experience. ⁶²	A C...G DI	36343222	2022
10	Primary Bilateral Intraosseous Rosai-Dorfman Disease. ⁶²	Foster CR...Habeeb O	36474405	2022
11	Multiagent Chemotherapy Followed by Stereotactic Body Radiotherapy Versus Conventional Radiotherapy for Resected Pancreas Cancer. ⁶²	Mokhtech M...Jethwa KR	36318696	2022
12	Clinical insights from Wolman disease: Evaluating infantile hepatosplenomegaly. ⁶²	Hannah WB...Kishnani PS	35972026	2022
13	Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin's Lymphoma. ⁶²	Castellino SM...Kelly KM	36322844	2022
14	Superficial and functional imaging of the tricipital lymphatic pathway: a modern reintroduction. ⁶²	Friedman R...Singhal D	36326995	2022
15	Cystic pancreatic neuroendocrine tumors: a multidisciplinary diagnostic challenge. ⁶²	Bazaga S...Mendez Coca I	35607931	2022
16	Incidental Parathyroidectomy Among Pediatric Patients Undergoing Thyroid Surgery. ⁶²	Ziai H...Wasserman JD	35191038	2022
17	Invited Commentary: Evolving Management of COVID-19 Vaccine-related Axillary Adenopathy. ⁶²	Weinstein S	36018787	2022
18	Unilateral Axillary Lymphadenopathy after the Inactivated SARSCOV-2 (CoronaVac) Vaccine: Ultrasonographic Imaging. ⁶²	Elverici E...Ozkan E	36421031	2022
19	Is MDCT an accurate tool to differentiate between benign and malignant etiology in diffuse peritoneal disease? ⁶²	George S...Eapen A	35978185	2022
20	Limiting Screening Mammography Recalls for Vaccine-Induced Adenopathy, a Single Institution Experience. ⁶²	Maimone S...Chumsri S	35090829	2022
21	Lymphoscintigraphic Findings of Scrotal Lymphangioma. ⁶²	Shen G...Kuang A	35383611	2022
22	Mammographic Findings of Diffuse Axillary Tail Trabecular Thickening After the Second Booster of COVID-19 Vaccination. ⁶²	Adam R...Maldjian T	36381885	2022
23	Recent advancement of imaging strategies of the lymphatic system: Answer to the decades old questions. ⁶²	Banerjee P...Chakraborty S	35972391	2022
24	Neuroendocrine carcinoma of the breast: A case report and review of the literature. ⁶²	Mouna H...Samouh N	36152367	2022
25	Superficial and Functional Lymphatic Anatomy of the Upper Extremity. ⁶²	Granoff MD...Singhal D	35939638	2022
26	Mycotic Pseudoaneurysm of the Aortic Arch. ⁶²	Goncalves J...Ferreira R	36197810	2022
27	TCL-360 A Case of Angioimmunoblastic T-Cell Lymphoma Presenting as Airway Obstruction. ⁶²	Saxena A...Khillan R	36164131	2022
28	Lymphatic Interventions in the Cancer Patient. ⁶²	Youssef EW...Santos E	35639331	2022
29	Hypertension in Cancer Survivors: A Review of the Literature and Suggested Approach to Diagnosis and Treatment. ⁶²	Chuquin D...Bottinor W	36027586	2022
30	Breast Cancer Screening and Axillary Adenopathy in the Era of COVID-19 Vaccination. ⁶²	Wolfson S...Kim E	36219117	2022
31	Perivascular infiltration reflects subclinical lymph node metastasis in invasive lobular carcinoma. ⁶²	Igawa A...Hakamada K	35947202	2022
32	Occult breast cancer presenting as axillary lymphadenopathy - Case Report. ⁶²	Camarneiro R...Brito E Melo M	36162357	2022
33	Clinical Significance of [18F] Fluoro-2-Deoxy-d-Glucose/Computed Tomographic Avid Hilar Lymph Nodes in Esophageal Carcinoma Patients. ⁶²	Feldman HA...Betancourt Cuellar SL	34634240	2022
34	Primary clear cell adenocarcinoma of the vagina not associated with diethylstilbestrol: A case report. ⁶²	Haddout S...El Karroumi M	35987029	2022
35	Trametinib for Refractory Chylous Effusions and Systemic Complications in Children with Noonan Syndrome. ⁶²	Nakano TA...Chatfield KC	35605646	2022
36	Sarcoidosis: A rare cause of penile edema. ⁶²	Herodotou CA...Mellon MJ	35992053	2022
37	Prevalence and 5-year trend of incidence for medical illnesses after the diagnosis of bipolar disorder: A nationwide cohort study. ⁶²	Chen PH...Kuo CJ	34558298	2022
38	From physical to ultrasound examination in lymphedema: a novel dynamic approach. ⁶²	Ricci V...Ozcakar L	35000129	2022
39	Impact of Morbid Obesity on the Outcomes of Type II Endometrial Cancer: a Cohort Study. ⁶²	Gaballa K...Hamdy M	36187516	2022
40	Prevention of early lymphatic disease in women with Robuvit®. A new supplementary solution? ⁶²	Hu S...Cotellese R	36178110	2022
41	Mediastinal metastases from a primary immature teratoma of the CNS. ⁶²	Zain SM...Mirchia K	35855860	2022
42	Does (Needle) Size Matter?: Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration for Mediastinal Adenopathy That Is Not Yet Diagnosed. ⁶²	Roy P...Gonzalez AV	36088088	2022
43	Axillary Adenopathy after COVID-19 Vaccine: No Reason to Delay Screening Mammogram. ⁶²	Wolfson S...Reig B	35994402	2022
44	Frequency and outcomes of MRI-detected axillary adenopathy following COVID-19 vaccination. ⁶²	Horvat JV...Feigin KN	35247087	2022
45	Unilateral Radiation Therapy for Tonsillar Cancer: Treatment Outcomes in the Era of Human Papillomavirus, Positron-Emission Tomography, and Intensity Modulated Radiation Therapy. ⁶²	Taku N...Garden AS	35504500	2022
46	Easy Scheme Outlining the Various Morphological and Vascular Abnormalities of the Lymph Node Structure Associated with Recent COVID-19 Vaccination, Each with a Different Clinical/Diagnostic Management. ⁶²	Fiaschetti V...Cossu E	36143157	2022
47	State-of-the-art imaging for lymphatic evaluation in children. ⁶²	Ramirez-Suarez KI...Biko DM	35980463	2022
48	Role of Angiopoietin-Tie axis in vascular and lymphatic systems and therapeutic interventions. ⁶²	Wang R...Huang M	35772646	2022
49	Dynamic Contrast-Enhanced Magnetic Resonance Lymphangiography and Lymphatic Interventions for Pediatric Patients with Various Lymphatic Diseases. ⁶²	Ahn Y...Shin JH	35984923	2022
50	Prognostic Factors of Survival in Patients with Peritoneal Metastasis from Colorectal Cancer. ⁶²	Mendoza-Moreno F...Gutierrez-Calvo A	36013160	2022

Sources

Genes for Lymphatic System Disease

Genes related to Lymphatic System Disease (0 elite genes):

(show top 50) (show all 107)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	MIR199A1	MicroRNA 199a-1	RNA Gene	14.87	DISEASES inferred ¹⁴ ¹⁴ ¹⁴
2	H2AC18	H2A Clustered Histone 18	Protein Coding	13.42	DISEASES inferred ¹⁴ ¹⁴
3	IRF4	Interferon Regulatory Factor 4	Protein Coding	13.33	DISEASES inferred ¹⁴ ¹⁴
4	CCR6	C-C Motif Chemokine Receptor 6	Protein Coding	13.03	DISEASES inferred ¹⁴ ¹⁴
5	MIR17	MicroRNA 17	RNA Gene	12.82	DISEASES inferred ¹⁴ ¹⁴
6	MIR155	MicroRNA 155	RNA Gene	12.71	DISEASES inferred ¹⁴ ¹⁴
7	U2AF1	U2 Small Nuclear RNA Auxiliary Factor 1	Protein Coding	12.64	DISEASES inferred ¹⁴ ¹⁴
8	ICOSLG	Inducible T Cell Costimulator Ligand	Protein Coding	12.49	DISEASES inferred ¹⁴ ¹⁴
9	MIR21	MicroRNA 21	RNA Gene	12.31	DISEASES inferred ¹⁴ ¹⁴
10	MIR15A	MicroRNA 15a	RNA Gene	11.83	DISEASES inferred ¹⁴ ¹⁴
11	MIR142	MicroRNA 142	RNA Gene	11.58	DISEASES inferred ¹⁴ ¹⁴
12	KDM4C	Lysine Demethylase 4C	Protein Coding	11.51	DISEASES inferred ¹⁴ ¹⁴
13	MIR9-1	MicroRNA 9-1	RNA Gene	11.41	DISEASES inferred ¹⁴ ¹⁴
14	MIR34A	MicroRNA 34a	RNA Gene	11.22	DISEASES inferred ¹⁴ ¹⁴
15	MIR181A1	MicroRNA 181a-1	RNA Gene	10.98	DISEASES inferred ¹⁴ ¹⁴
16	MIR126	MicroRNA 126	RNA Gene	10.97	DISEASES inferred ¹⁴ ¹⁴
17	SERPINA3	Serpin Family A Member 3	Protein Coding	10.88	DISEASES inferred ¹⁴ ¹⁴
18	MIR150	MicroRNA 150	RNA Gene	10.74	DISEASES inferred ¹⁴ ¹⁴
19	MIR18A	MicroRNA 18a	RNA Gene	10.71	DISEASES inferred ¹⁴ ¹⁴
20	MIR200B	MicroRNA 200b	RNA Gene	10.71	DISEASES inferred ¹⁴ ¹⁴
21	MIR125A	MicroRNA 125a	RNA Gene	10.68	DISEASES inferred ¹⁴ ¹⁴
22	MIR145	MicroRNA 145	RNA Gene	10.6	DISEASES inferred ¹⁴ ¹⁴
23	MIR20A	MicroRNA 20a	RNA Gene	10.58	DISEASES inferred ¹⁴ ¹⁴
24	MIR140	MicroRNA 140	RNA Gene	10.57	DISEASES inferred ¹⁴ ¹⁴
25	MIR92A1	MicroRNA 92a-1	RNA Gene	10.54	DISEASES inferred ¹⁴ ¹⁴
26	MIR196A1	MicroRNA 196a-1	RNA Gene	10.47	DISEASES inferred ¹⁴ ¹⁴
27	MIR221	MicroRNA 221	RNA Gene	10.37	DISEASES inferred ¹⁴ ¹⁴
28	MIR146A	MicroRNA 146a	RNA Gene	10.36	DISEASES inferred ¹⁴ ¹⁴
29	MIR27A	MicroRNA 27a	RNA Gene	10.35	DISEASES inferred ¹⁴ ¹⁴
30	MIR223	MicroRNA 223	RNA Gene	10.34	DISEASES inferred ¹⁴ ¹⁴
31	MIR30A	MicroRNA 30a	RNA Gene	10.27	DISEASES inferred ¹⁴ ¹⁴
32	MIR29B1	MicroRNA 29b-1	RNA Gene	10.19	DISEASES inferred ¹⁴ ¹⁴
33	MIR93	MicroRNA 93	RNA Gene	10.15	DISEASES inferred ¹⁴ ¹⁴
34	MIR214	MicroRNA 214	RNA Gene	10.13	DISEASES inferred ¹⁴ ¹⁴
35	MIR143	MicroRNA 143	RNA Gene	10.12	DISEASES inferred ¹⁴ ¹⁴
36	BCL2	BCL2 Apoptosis Regulator	Protein Coding	10.12	DISEASES inferred ¹⁴
37	MIR125B1	MicroRNA 125b-1	RNA Gene	10.12	DISEASES inferred ¹⁴ ¹⁴
38	MIR29A	MicroRNA 29a	RNA Gene	10.06	DISEASES inferred ¹⁴ ¹⁴
39	MIR15B	MicroRNA 15b	RNA Gene	10.04	DISEASES inferred ¹⁴ ¹⁴
40	MIR222	MicroRNA 222	RNA Gene	9.98	DISEASES inferred ¹⁴ ¹⁴
41	MIR31	MicroRNA 31	RNA Gene	9.95	DISEASES inferred ¹⁴ ¹⁴
42	MIR28	MicroRNA 28	RNA Gene	9.95	DISEASES inferred ¹⁴ ¹⁴
43	MIR106A	MicroRNA 106a	RNA Gene	9.86	DISEASES inferred ¹⁴ ¹⁴
44	MIRLET7A1	MicroRNA Let-7a-1	RNA Gene	9.82	DISEASES inferred ¹⁴ ¹⁴
45	MIR24-1	MicroRNA 24-1	RNA Gene	9.81	DISEASES inferred ¹⁴ ¹⁴
46	MIR423	MicroRNA 423	RNA Gene	9.79	DISEASES inferred ¹⁴ ¹⁴
47	MIR486-1	MicroRNA 486-1	RNA Gene	9.78	DISEASES inferred ¹⁴ ¹⁴
48	MIR16-1	MicroRNA 16-1	RNA Gene	9.78	DISEASES inferred ¹⁴ ¹⁴
49	MIR106B	MicroRNA 106b	RNA Gene	9.77	DISEASES inferred ¹⁴ ¹⁴
50	MIR127	MicroRNA 127	RNA Gene	9.73	DISEASES inferred ¹⁴ ¹⁴

Sources

Variations for Lymphatic System Disease

Sources

Expression for Lymphatic System Disease

Search GEO for disease gene expression data for Lymphatic System Disease.

Sources

Pathways for Lymphatic System Disease

Pathways related to Lymphatic System Disease according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	miRNAs involved in DNA damage response ⁷⁴	11.38	MIR21 MIR18A MIR181A1 MIR17 MIR15A
2	Cell differentiation - expanded index ⁷⁴ Show member pathways Cell differentiation - index ⁷⁴	11.33	MIR9-1 MIR199A1 MIR181A1 MIR17 MIR155 MIR150
3	Interactions between immune cells and microRNAs in tumor microenvironment ⁷⁴	11.11	MIR34A MIR21 MIR200B
4	miRNAs involvement in the immune response in sepsis ⁷⁴	10.89	MIR9-1 MIR21 MIR200B MIR199A1 MIR155 MIR126

Sources

GO Terms for Lymphatic System Disease

Cellular components related to Lymphatic System Disease according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular space	GO:0005615	9.9	SERPINA3 MIR21 MIR199A1 MIR18A MIR181A1 MIR17
2	RISC complex	GO:0016442	9.7	MIR9-1 MIR21 MIR200B MIR199A1 MIR18A MIR181A1
3	extracellular vesicle	GO:1903561	9.35	MIR34A MIR21 MIR17 MIR15A MIR126

Biological processes related to Lymphatic System Disease according to GeneCards Suite gene sharing:

(show all 14)

#	Name	GO ID	Score	Top Affiliating Genes
1	negative regulation of cell migration	GO:0030336	9.84	MIR9-1 MIR34A MIR21 MIR126
2	negative regulation of gene expression	GO:0010629	9.8	MIR155 MIR17 MIR199A1 MIR200B MIR21 MIR34A
3	negative regulation of inflammatory response	GO:0050728	9.73	MIR199A1 MIR15A MIR142 MIR126
4	negative regulation of angiogenesis	GO:0016525	9.71	MIR34A MIR21 MIR200B MIR15A
5	miRNA-mediated gene silencing	GO:0035195	9.7	MIR9-1 MIR34A MIR21 MIR200B MIR199A1 MIR18A
6	negative regulation of sprouting angiogenesis	GO:1903671	9.54	MIR34A MIR18A MIR17
7	positive regulation of connective tissue replacement	GO:1905205	9.52	MIR34A MIR199A1
8	negative regulation of vascular wound healing	GO:0061044	9.51	MIR34A MIR200B
9	negative regulation of vascular associated smooth muscle cell migration	GO:1904753	9.5	MIR34A MIR21 MIR15A
10	positive regulation of cardiac muscle hypertrophy in response to stress	GO:1903244	9.49	MIR199A1 MIR17
11	negative regulation of vascular associated smooth muscle cell apoptotic process	GO:1905460	9.48	MIR21 MIR17
12	positive regulation of metalloendopeptidase activity	GO:1904685	9.46	MIR21 MIR17
13	negative regulation of vascular endothelial growth factor production	GO:1904046	9.46	MIR34A MIR199A1 MIR17 MIR15A
14	miRNA-mediated gene silencing by inhibition of translation	GO:0035278	9.43	MIR9-1 MIR21 MIR200B MIR17 MIR15A MIR126

Molecular functions related to Lymphatic System Disease according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	mRNA 3'-UTR binding	GO:0003730	9.65	MIR9-1 MIR34A MIR21 MIR200B MIR199A1 MIR17
2	mRNA base-pairing translational repressor activity	GO:1903231	9.4	MIR9-1 MIR34A MIR21 MIR200B MIR199A1 MIR18A